- Home
- PCB vs VRCA Comparison
PCB vs VRCA Comparison
Compare PCB & VRCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCB
- VRCA
- Stock Information
- Founded
- PCB 2003
- VRCA 2013
- Country
- PCB United States
- VRCA United States
- Employees
- PCB N/A
- VRCA N/A
- Industry
- PCB Major Banks
- VRCA Biotechnology: Pharmaceutical Preparations
- Sector
- PCB Finance
- VRCA Health Care
- Exchange
- PCB Nasdaq
- VRCA Nasdaq
- Market Cap
- PCB 308.3M
- VRCA 363.1M
- IPO Year
- PCB N/A
- VRCA 2018
- Fundamental
- Price
- PCB $20.29
- VRCA $0.64
- Analyst Decision
- PCB Hold
- VRCA Hold
- Analyst Count
- PCB 2
- VRCA 5
- Target Price
- PCB $22.00
- VRCA $6.00
- AVG Volume (30 Days)
- PCB 27.3K
- VRCA 780.8K
- Earning Date
- PCB 01-23-2025
- VRCA 11-04-2024
- Dividend Yield
- PCB 3.47%
- VRCA N/A
- EPS Growth
- PCB N/A
- VRCA N/A
- EPS
- PCB 1.68
- VRCA N/A
- Revenue
- PCB $94,833,000.00
- VRCA $9,210,000.00
- Revenue This Year
- PCB N/A
- VRCA $54.16
- Revenue Next Year
- PCB $10.34
- VRCA $99.78
- P/E Ratio
- PCB $12.35
- VRCA N/A
- Revenue Growth
- PCB N/A
- VRCA 187.45
- 52 Week Low
- PCB $14.50
- VRCA $0.62
- 52 Week High
- PCB $22.20
- VRCA $11.41
- Technical
- Relative Strength Index (RSI)
- PCB 39.88
- VRCA 28.48
- Support Level
- PCB $21.17
- VRCA $1.11
- Resistance Level
- PCB $21.77
- VRCA $1.32
- Average True Range (ATR)
- PCB 0.54
- VRCA 0.12
- MACD
- PCB -0.18
- VRCA -0.03
- Stochastic Oscillator
- PCB 9.05
- VRCA 3.13
About PCB PCB Bancorp
PCB Bancorp is a bank holding company, which engages in the provision of consumer and commercial banking services. It provides Personal, Business, and Loan services, which provide banking, lending, and digital, tools, home loans, and others. Also, it offers a broad range of loans, deposits, and other products and services predominantly to small and middle-market businesses and individuals.
About VRCA Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.